Does resveratrol reduce cisplatin-induced ovarian damage?

Area of Science:

• Reproductive toxicology
• Pharmacology
• Biochemistry

Background:

• Cisplatin is a widely used chemotherapy agent with known ovarian toxicity.
• Ovarian damage can lead to infertility and other reproductive complications.
• Resveratrol, a natural polyphenol, has demonstrated antioxidant and anti-inflammatory properties.

Purpose of the Study:

• To evaluate the protective effects of resveratrol against cisplatin-induced ovarian damage.
• To assess the impact of resveratrol on biochemical and histopathological parameters of ovarian injury.
• To investigate resveratrol's influence on oxidative stress markers in the ovary.

Main Methods:

• Female Wistar-Albino rats were divided into three groups: control (NaCl), cisplatin-induced damage, and cisplatin plus resveratrol.
• Ovarian tissues were analyzed using histopathological examination and scoring.
• Biochemical assays were performed to measure malondialdehyde (MDA), catalase (CAT), and superoxide dismutase (SOD) levels.
• Immunohistochemical staining for c-kit expression was used to assess ovarian function.

Main Results:

• Cisplatin administration significantly increased the histopathological findings score, indicating ovarian damage.
• Resveratrol treatment (Group 3) showed significantly higher superoxide dismutase and catalase levels compared to the cisplatin-only group (Group 2).
• Malondialdehyde levels were significantly elevated in the cisplatin-induced damage group (Group 2) compared to the resveratrol-treated group (Group 3).

Conclusions:

• Resveratrol demonstrated a protective effect against cisplatin-induced ovarian injury in experimental models.
• Resveratrol administration improved key biochemical parameters, including antioxidant enzyme activity and lipid peroxidation markers.
• These findings suggest resveratrol's potential as a therapeutic agent to mitigate chemotherapy-induced ovarian toxicity.